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ABSTRACT - Betatherapy is a radiotherapy modality that uses beta radiation applicators 
used in the treatment of superficial injuries. With the advancement of therapeutic 
techniques, new clinical protocols of veterinary medicine will be established and 
betatherapy emerges as an important option for performing radiotherapy procedures, 
and further studies for the definition of oncological clinical protocols become necessary. 
This study reports some procedures in animals involving intraoperative betatherapy with 
a strontium-90 applicator (90Sr). Five procedures were performed, including 1 lioness 
(Panthera leo), 2 rats (Rattus norvegicus), 1 equine female (Equidae) and 1 rabbit 
(Oryctolagus cuniculus), all with a confirmed diagnosis of neoplasm. The TDF (Time-
Dose-Fraction) radiographic model was used to determine the radiological equivalent of 
the clinical cases. It was observed that the neoplasms in each case (1 to 5) partially 
differed from those found in the literature on intraoperative betatherapy in veterinary 
medicine. We observed that the radiologic effectiveness of the treatment was directly 
related to the value of TDF. Cases 1, 3 and 4 presented TDF values greater than 175, 
which implies a greater probability of injury control. As observed in the follow-up of the 
patients, case 5 (lower TDF) presented tumor recurrence only one month after the 
betatherapy procedure. Betatherapy with Sr90 applicators has proven to be feasible and 
easy to handle for the clinical cases analyzed in this study, especially during 
intraoperative procedures. 
Key words - brachytherapy; strontium-90; veterinary medicine. 
 
RESUMO - A betaterapia é uma modalidade de radioterapia que utiliza aplicadores de 
radiação beta, os quais são usados no tratamento de lesões superficiais.  Com o avanço 
das técnicas terapêuticas, novos protocolos clínicos da medicina veterinária serão 
estabelecidos e a betaterapia surge como uma opção importante para a realização de 
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procedimentos radioterápicos e consequente estudos para definições de protocolos 
clínicos oncológicos. O presente estudo relata alguns procedimentos em animais 
envolvendo betaterapia intraoperatória com aplicador de estrôncio-90 (Sr90). Cinco 
procedimentos foram realizados, incluindo 1 leoa (Panthera leo), 2 ratas (Rattus 
norvegicus), 1 fêmea equina (Equidae) e 1 coelho (Oryctolagus cuniculus), sendo todos 
com neoplasia confirmada. O modelo radiobiológico do TDF (Tempo-Dose-Fração) foi 
usado para determinar o equivalente radiobiológico dos casos clínicos. As neoplasias 
acompanhadas em cada caso (1 a 5) diferiram parcialmente das que foram identificadas 
na literatura consultada sobre a betaterapia intraoperatória em medicina veterinária. Foi 
observado que a efetividade radiobiológica do tratamento está diretamente relacionada 
com o valor do TDF. Os casos 1, 3 e 4 apresentaram valores de TDF maiores do que 
175, o que implica em maior probabilidade de controle da lesão. Conforme observado 
no seguimento dos pacientes, o caso 5 (menor TDF) apresentou recidiva tumoral com 
apenas um mês após o procedimento betaterápico. A betaterapia com aplicadores de 
Sr90 mostrou-se exequível e de fácil manuseio para os casos clínicos analisados neste 
estudo, principalmente nos procedimentos intraoperatórios.  
Palavras-chave - braquiterapia; estrôncio-90; medicina veterinária. 
 
INTRODUCTION  
Radiotherapy is the medical modality that uses sources of ionizing radiation to 
treat diseases, especially cancer (Mcniel, 2009). In veterinary medicine, the use of 
radiotherapy is already established in several countries. In Brazil it is still a procedure 
under study, but the applications of radiotherapy in veterinary have shown excellent 
results (Fernandes et al., 2010). The feasibility of the technique depends mainly on the 
consolidation of the procedures and the success of the therapeutic proposal (Fernandes 
et al., 2003). 
Radiotherapy in veterinary medicine has found a strong focus in the therapeutic 
results offered (Andrade and Fernandes, 2015). According to reports in the literature, 
radiotherapy started in 1927 and, since then, this oncological modality has been growing 
all around the world (Burk and King, 1997). Research involving this therapeutic modality 
in animals is growing slowly in Brazil, and the studies point to the need for a deeper 
understanding of the techniques performed and better knowledge of the applied 
radiation sources (Vettorato et al., 2017; Vettorato et al., 2019). 
Betatherapy is a modality of radiotherapy (brachytherapy) that uses beta radiation 
applicators and is widely used in the treatment of superficial injuries since beta particles 
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have great ionization power and small reach in the tissue, which means that beta 
applicators accumulate large doses over small volumes (Scaff, 2010). This practice has 
become increasingly more available and has been applied in the treatment of neoplasm 
in several animal species using strontium-90 (90Sr) (Andrade et al., 2004; Kent 2017). 
90Sr refers to a radioactive element that can be placed on the surface of a tumor 
to provide radiation. In this case, the maximum dose is administered on the surface and 
decreases rapidly, with only about 10% of the administered dose reaching a depth of 3 
mm (Fernandes et al., 2007). This property has advantages and disadvantages. Delivering 
the dose superficially means that it is not effective for deep tumors, but it has the 
advantage of preventing the dose from reaching deeper and normal tissues, which means 
that a high dose can be administered without damage to the underlying normal tissue 
(Kent, 2017). The probe is usually held in a device during treatment to minimize personal 
exposure, although the dose rate is determined by the age of the individual probe, most 
treatments can be done in 3 to 5 minutes per application (Fernandes et al., 2007; Kent, 
2017). 
With the advancement of therapeutic techniques, new clinical protocols in 
veterinary medicine will be established. In this sense, betatherapy appears as an 
important option for performing radiotherapy procedures and further studies are needed 
for the definition of oncological clinical protocols. This study reports some procedures in 
animals involving intraoperative betatherapy with a 90Sr applicator at the School of 
Veterinary Medicine and Animal Science (FMVZ), São Paulo State University (UNESP) and 
the feasibility of this practice in veterinary oncology. 
 
MATERIALS AND METHODS 
This research was approved by the FMVZ/UNESP Ethics Committee on the Use of 
Animals (CEUA) (Protocol No. 0050/2017). 
The procedures were performed on five animals belonging to the FMVZ (1 lioness 
(Panthera leo), 2 rats (Rattus norvegicus), 1 female horse (Equidae) and 1 rabbit 
(Oryctolagus cuniculus), all of which had a confirmed diagnosis of neoplasm. 
All betatherapy procedures were performed with the same 90Sr applicator (model 
Amershan - SIA 20-1102 ML), calibrated at the Brazilian Institute for Energy and Nuclear 
Research (IPEN/CNEN-SP) calibration laboratory on 13/01/2009. 
The Time-Dose-Fraction (TDF) radiobiological model (ORTON and ELLIS, 1973) was 
used to determine the radiobiological equivalent of the clinical cases treated in this work. 
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RESULTS 
In the first case (1) is of a lioness (Panthera leo), approximately 14 years old, 
unneutered, obtained from a private breeding ground. The animal was sent to the Center 
for Medicine and Research on Wild Animals (CEMPAS) with a history of weight loss and 
possible recurrent vaginal prolapse 2 months ago. 
After applying chemical restraint, the physical condition of the animal was 
examined, revealing a pedunculated mass approximately 20 cm in length, reddish in color 
and fibroelastic consistency, located on the floor of the vagina. The mass was submitted 
to cytopathological and histopathological exams, the results being compatible with 
leiomyosarcoma. 
The animal was submitted to general inhalation anesthesia so a computed 
tomography exam could be performed in the diagnostic imaging sector. The tomography 
was performed on a Shimadzu CT scanner (model SCT 7800 TC Helicoidal 1-channel), 
before and after the injection of intravenous contrast, in order to characterize the 
location and extent of the neoplasm and plan the surgery and betatherapy. In the 
images, the presence of vaginal mass was noted, with soft tissue attenuation values 
between 20 and 60 Hounsfield Units (HU), measuring approximately 14.0 cm x 4.32 cm x 
4.76 cm (craniocaudal x dorsoventral x lateral) and showing slight homogeneous 
enhancement after injection of the contrast medium. 
The surgical procedure was then chosen, and the mass was excised at its base 
before betatherapy was applied. The urethra was kept probed during the intervention to 
avoid iatrogenic trauma.  
Betatherapy was performed on February 5, 2016, the current radioactive activity of 
plate 1 was 34.21 mCi / 1265.32 MBq and the dose rate was 27.24 cGy/s. The animal 
received a single dose fraction, which was distributed in 12 fields due to the extent of the 
injury and the size of the active volume of plate 1. The exposure time in each radiation 
field was two minutes, corresponding to a dose of radiation of 3,269 cGy (in each field). 
The radiotherapy procedure lasted for a total time of 24 minutes. Next, the vaginal 
mucosa was sutured. 
The animal showed good recovery and, two weeks after the procedure underwent 
a tomographic examination, which revealed a circumscribed area with partially defined 
edges was visible, with soft tissue attenuation values, approximately between 20 and 60 
HU, measuring about 4.50 cm x 3.85 cm x 4.24 cm (craniocaudal x dorsoventral x lateral), 
located on the vaginal bottom and without evidence of enhancement after injection of 
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the intravenous contrast medium, but causing a slight dorsal displacement of the final 
portion of the descending colon. The images suggested a healing process in the vaginal 
fundus, considering the injury in involution. The animal returned to its place of origin 
and, after six months, died from accidental causes unrelated to the neoplasm. 
The second case (2) refers to a female Wistar rat (Rattus norvegicus), belonging to 
a vivarium, which was referred to CEMPAS due to an increase in volume in the abdominal 
wall region, whose evolution time has not been determined. 
Upon physical examination, there was an extensive and firm increase in volume, 
located in the region of the thoracic and abdominal mammary glands, suggestive of a 
tumor. Contrast computed tomography was performed in order to determine the extent 
of the neoplasm for surgical and betatherapy planning. 
The tomographic images showed the presence of the mass in the abdominal wall, 
with attenuation values of approximately 50 HU to 60 HU, measuring about 6.12 cm x 
4.32 cm x 4.82 cm (craniocaudal x dorsoventral x lateral). 
Betatherapy was performed on March 29, 2018, the current activity of plaque 1 
was 32.47 mCi / 1201.39 MBq and the dose rate was 25.86 cGy/s. With the animal under 
general injectable anesthesia, a total unilateral mastectomy was performed. After surgical 
excision of the tumor mass, the animal had a cardiorespiratory arrest during the exposure 
of the fourth field and died. The time for each field was one minute, 1552 cGy per field. 
Figure 1 illustrates intraoperative betatherapy, after tumor excision. The tumor mass was 
forwarded for histopathological examination, the result of which was simple tubular 
breast carcinoma. 
The third case (3) was a female Wistar rat (Rattus norvegicus), belonging to a 
vivarium, which was referred to CEMPAS due to the presence of a nodule in the right 
inguinal region observed for approximately 15 days. Upon examination, a well-
circumscribed nodule of approximately 11 cm in diameter was observed, affecting the 
region of the right abdominal and inguinal breasts, with a multilobed aspect, firm 
consistency, not adhered and not ulcerated. The cytological examination of the mass was 
suggestive of carcinoma. 
A computed tomography scan with contrast was performed to characterize the 
location and extent of the neoplasm and plan the surgical procedure and betatherapy. 
The images demonstrated the presence of the mass with attenuation values between 50 
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Figure 1 - Betatherapy applied to the surgical bed, after excision 
of a mammary tumor, in a female Wistar rat - Rattus norvegicus 
(Case 2). 
 
Betatherapy was performed on June 28, 2018, the activity of the betatherapy plate 
was 32.27 mCi / 1194.13 MBq and the dose rate was 25.70 cGy / s. With the animal 
under general inhalation anesthesia with isoflurane, a regional mastectomy was 
performed including right abdominal and inguinal breasts. After surgical excision of the 
tumor mass, the animal received a single fraction of a dose of 3084 cGy, released in each 
of the nine treatment fields. The irradiation time per field was two minutes. The total time 
of the betatherapy procedure was 18 minutes. The animal did not evolve properly in the 
postoperative period, with reduced food intake, before dying three days later. The mass 
was forwarded for histopathological examination, the result of which was fibroadenoma.  
The fourth case (4) analyzed refers to a female horse (Equidae), belonging to a 
private property in the Rubião Júnior District in Botucatu - SP, Brazil, which was referred 
to FMVZ, due to the presence of volume increases in the orbital region for approximately 
three months. Upon physical examination, multinodular dermal tumor masses located in 
the infra and left supra-orbital regions were found, with the presence of ulceration. A 
histopathological biopsy confirmed the diagnosis of cutaneous schwannoma. 
Betatherapy was performed on April 8, 2016, the radioactive activity of the Sr90 
applicator was 34.07 mCi / 1260.42 MBq with a dose rate of 27.13 cGy/s. The surgical 
procedure was performed at the private property. Therefore, the animal was sedated with 
detomidine and anesthetic block with lidocaine was applied to the infratrochlear, 
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supraorbital, lacrimal and zygomatic nerves. After tumor excision, the animal received a 
single dose fraction, which was distributed in 16 radiation fields, 10 fields in the infra-
orbital region and six supra-orbital fields. Each field was exposed to a radiation time of 
two minutes corresponding to a dose of 3,256 cGy. The total procedure time was 32 
minutes. Figure 2 illustrates the intraoperative betatherapy of the horse (Equidae). 
 
 
Figure 2 - Betatherapy procedure performed in 
the orbital region in an equine - Equidae (Case 4). 
 
The animal presented good recovery during the first months (Figure 3). In the 
sixth month after the procedure, the owner reported that the female horse (Equidae) was 
pregnant and without signs of local tumor recurrence. 
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Figure 3 - Animal recovery after four 
months of the betatherapy procedure (Case 
4). 
 
The fifth case (5) was a six-year-old male rabbit (Oryctolagus cuniculus) from a 
private property, who was referred to CEMPAS due to hypoxia and swelling at the base 
of the ear for about 25 days. Physical examination identified a tumor mass of 
approximately 3.5 X 3.0 X 2.5, bilobed, non-ulcerated, fibroelastic, adhered, located on 
the face near the base of the right ear. 
A cytopathological examination was performed, which was suggestive of 
malignant epithelial neoplasia of cutaneous attachment. Additionally, radiographic 
examinations of the head and thorax were performed, revealing no bone involvement or 
signs suggestive of lung metastasis. 
Betatherapy was performed on April 26, 2019, at the time, the 90Sr plaque activity 
was 31.63 mCi / 1170.34 MBq and the dose rate was 25.19 cGy/s. For the procedure, the 
rabbit (Oryctolagus cuniculus) was sedated with midazolam and morphine, followed by 
general inhalation anesthesia with isoflurane. After excision of the tumor mass with a 
margin of around 1-1.5 cm, the animal received a single fraction of a radiation dose of 
1,511 cGy in each of the 11 treatment fields with an exposure time of one minute in each 
field. The total procedure time was 11 minutes. 
Subsequently, the tissues were approached with sutures. As it was an old animal 
and due to the risks related to anesthetic maintenance, the previously described exposure 
time was chosen. Figure 4 illustrates the intraoperative betatherapy of the rabbit 
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(Oryctolagus cuniculus) after excision of the tumor mass. The mass was forwarded for 
histopathological examination, the result of which was a poorly differentiated malignancy. 
 
 
Figure 4 - Intraoperative betatherapy 
procedure, after excision of a tumor mass 
located on the face, near the base of the 
right ear, in a rabbit (Oryctolagus cuniculus). 
(Case 5). 
 
The animal returned to the owner the following week and during the first month 
after the operation presented good recovery. In the second month after the procedure, 
other tumor masses appeared, one in the region of the right pinna and the other in the 
region of the face close to the zygomatic bone. Due to the animal's advanced age, 
palliative therapies (nutraceutical, ozonized oil and acupuncture) were chosen. The animal 
died four months after the betatherapy procedure, due to a cause unrelated to the 
tumor. 
Table 1 explains the main information about the five clinical cases followed at FMVZ. The 
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Table 1 - Betatherapy procedures performed at FMVZ/UNESP. 






























34.21/ 1265.32 32.47/ 1201.39 32.27/1194.13 34.07/1260.42 31.63/ 1170.34 
Dose rate 
(cGy/s) 27.24 25.86 25.70 27.13 25.19 
Number of 
fractions 1 1 1 1 1 
Number of 








1440 240 1080 1920 660 
Total dose 
(cGy) 3,269 1,552 3,084 3,256 1,511 
Legend: mCi/MBq = milicurie/Megabecquerel; cGy/s = centigray per second. 
 
 
Table 2 - TDF values for the treated clinical cases. 
Case cGy/s Exposure Dose Number of d1,538 TDF 
 Mean time (s) (cGy) fractions   
1 27.464 120 3.296 1 257,397.100 193.46 
2 26.070 60 1.564 1 81,813.020 61.49 
3 25.914 120 3.110 1 235,397.464 176.93 
4 27.351 120 3.282 1 255,767.171 192.24 
5 25.396 60 1.524 1 78,584.137 59.06 
Legend: cGy/s = centigray per second; TDF = Time-Dose-Fraction. 
 
DISCUSSION 
Regarding the tumor types referring to the animal species of each case (1 to 5), 
these apparently differed from those already described about betatherapy in veterinary 
medicine (Rebhun, 1998; Théon and Feldman, 1998; Knottenbelt and Kelly, 2000; Reed 
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and Bayly, 2000; Andrade et al., 2004; Mcentee, 2004; Mosunic et al., 2004; Goodfellow et 
al., 2006; Turrel et al., 2006; Donaldson et al., 2006ab; Hammond et al., 2007; Plummer et 
al., 2007; Montgomery et al., 2010; Nagata et al., 2011; Pignon et al., 2011; Ware and 
Gieger, 2011; Gardhouse et al., 2014; Nickilin et al., 2014; Knottenbelt et al., 2015; Nevile 
et al., 2015; Brandão et al., 2015; Berlato et al., 2016; Kent, 2017). 
Although reports of betatherapy in lion (Panthera leo) have not been identified, 
there are several studies with 90Sr in domestic cats, used for the treatment of oral and 
nasal squamous cell carcinoma, mastocytomas, melanomas, limb hemangiosarcomas and 
superficial eye conditions and conditions benign (Godden, 1988; Goodfellow et al., 2006; 
Turrel et al., 2006; Donaldson et al., 2006ab; Hammond et al., 2007; Montgomery et al., 
2010; Nagata et al., 2011). The radiation dose used in the lion (Panthera leo) was 3,269 
cGy, distributed in 12 fields, which allowed the tumor to be controlled during 
observation. In cats (Felis catus) with mastocytomas, the radiation dose has varied from 
120 to 150 cGy, in varying numbers of fields (1 to 9), with an average survival time of 
1075 days (Turrel et al., 2006). For squamous cell carcinoma in cats (Felis catus), the 
radiation dose was 5000 cGy administered in five fractions, which prevented the disease 
from recurring during a follow-up period of 134 to 2043 days (Goodfellow et al., 2006). In 
addition, in a study with 11 domestic dogs (Canis lupus familiaris) in which partial 
cystectomy was performed due to transitional cell carcinoma, betatherapy with 90Sr was 
performed in four applications of five minutes of exposure, totaling a dose of 3000 cGy, 
and no tumor recurrence was observed during a six-month follow up period (Andrade et 
al., 2004). 
In the two cases of spontaneous neoplasia in rats (Rattus norvegicus), a simple 
tubular mammary carcinoma and another of fibroadenoma, the single radiation doses 
were 1552 and 3084 cGy, respectively, which were considered safe for the size of the 
animals. However, it was not possible to evaluate the evolution of the treatment, since 
both animals died. In a study on the effects of beta radiation on the healing of skin 
wounds in rats (Rattus norvegicus albinus, Rodentia mammalia), a 1.5 cm 90Sr plate with 
an activity of 50 mCi and an energy of 0.54 megaelectronsvolts (MeV) was also used), 
using 10 fractions at a dose of 250 cGy, with an exposure time of 13.8 seconds each, 
totaling a maximum dose of 2500 cGy (Pereira-Filho et al. 1998), which is a total dose 
similar to that used in the aforementioned cases. 
Although there are reports of cutaneous Schwannomas in horses (Equidae), these 
tumors are considered infrequent in the species (Schöniger et al., 2011). In this study, the 
female horse (Equidae) with cutaneous Schwannomas in the supra and infra-orbital 
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regions responded positively to intraoperative betatherapy with 90Sr, with single radiation 
doses of 3256 cGy. Generally, in horses (Equidae), intraoperative treatment with 90Sr is 
performed to treat the residual tumor after incomplete excision (Théon and Feldman, 
1998). In cases of periorbital sarcoids, there are reports of radiation doses of 10,000 cGy, 
divided across 5 days, during 5 minutes of exposure (Knottenbelt and Kelly, 2000). On the 
other hand, in cases of periocular squamous cell carcinomas, the local radiation doses 
were 25,000 cGy, which had a success rate of 89% and had no reports of complications. 
Therefore, there is a difference in doses. Andrade et al. (2015) evaluated the efficacy of 
betatherapy with 90Sr as a unique treatment modality in squamous cell carcinomas of the 
third eyelid of nine dogs (Canis lupus familiaris), which was administered in four fractions 
of 100 cGy per site every four days. Betatherapy was well tolerated in all cases, but there 
was local tumor recurrence in two animals after 150 days and 352 days, and in the other 
seven, the disease-free interval ranged between 1239 and 2555 days. 
The rabbit (Oryctolagus cuniculus) with malignant epithelial neoplasia of the 
cutaneous annex evaluated in this study showed very rapid tumor recurrence after 
treatment. One hypothesis was that the exposure time (60 seconds) and the radiation 
dose (1511 cGy) used in the procedure were of insufficient potency, since this type of 
neoplasm is very aggressive and due to the location of the injury, may not have been 
removed to a sufficient extent. There is a report of a case of amelanotic melanoma in a 
rabbit (Oryctolagus cuniculus), in which radiotherapy with 90Sr in a single dose of 15,000 
cGy radiation for each of the three fields of the lesion and exposure time of six minutes 
on the resected surgical bed surface (activity of the radioactive source of 27.6 mCi and 
dose rate of 41.7 cGy/s) presented a survival time of six months without signs of local 
recurrence (Brandão et al., 2015). 
In this study, no adverse reactions were detected due to beta radiation in the 
assisted animals. However, the side effects of betatherapy have already been evaluated in 
some rodent species and, in general, the tissues affected by beta radiation have changed 
similarly to those treated by comparable doses of X-rays (Friedell, 1951; Friedell, 1954; 
Snider and Raper, 1951; Fukuyama et al., 1959). In the eyelids of dogs (Canis lupus 
familiaris) and cats (Felis catus), corneal healing, conjunctivitis, keratopathy and 
subsequent effects, such as scleral thinning and focal scleromalacia, have been described 
as adverse effects (Donaldson et al., 2006b; Nagata et al., 2011; Nevile et al., 2015). In 
dogs (Canis lupus familiaris), less than three months after treatment, conjunctivitis, 
corneal scarring, granulation tissue formation, focal scleromalacia, deep sclerism, globe 
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perforation, sectoral cortical cataract, localized bullous keratopathy and corneal lipidosis 
were identified; whereas over three months, deep scleral slippage, lipid keratopathy, deep 
scleromalacia, deep scleral tuning, deep scleral thinning, globe perforation and lipid 
keratopathy were detected (Donaldson et al., 2006ab). 
The use of betatherapy in veterinary oncology has proven to be feasible for the 
clinical cases analyzed in this research. The therapeutic result achieved is directly related 
to the animal's clinical conditions, disease staging and, mainly, dependent on the quality 
of the applied radiation dose distribution. The feasibility of the betatherapy procedure 
involves a multidisciplinary team composed mainly of veterinarians with knowledge in 
oncology, medical physicists, and technologists in radiology, all with adequate training in 
radiotherapy and radiological protection. 
 
CONCLUSIONS 
Betatherapy with 90Sr applicators proved to be feasible and easy to handle for the 
clinical cases analyzed in this work. The radioactive sources emitting beta particles do not 
require great care with radiological protection in comparison with other radioactive 
sources, which contributes to the viability of their handling in veterinary radiotherapy, 
especially in intraoperative procedures. 
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